GET IN TOUCH

Alcidion appoints new Independent Non-Executive Directors

Alcidion Group Limited (‘Alcidion’ or the ‘Company’) today announced Ms Victoria Weekes and Mr Daniel Sharp will join the Alcidion Board as Independent Non-Executive Directors, effective 1 September 2021.

The appointments follow a considered search by Alcidion to sustain and broaden the mix of skills and experience on its board, and board and committee succession planning. The appointments fill the vacancies created by the resignation of Alcidion co-founder Raymond Blight on 30th June 2020 and Mr Nick Dignam who resigns on rotation and as part of the Board’s renewal program at the Annual General Meeting in November this year.

Ms. Weekes was the immediate past Acting Chair of the Sydney Local Health District Board and is an experienced Non-Executive Director with current appointments including FINSIA, NSW Treasury Audit and Risk, and St George Community Housing. Ms. Weekes will Chair Alcidion’s Audit and Risk Committee, noting her considerable experience in the banking and finance sectors.

Ms. Weekes has Bachelors Commerce and Law from UNSW, is a Senior Fellow of FINISA, Fellow of Australian Institute of Company Directors, and a Chartered Banker.

Mr Sharp is an investment banker with more than 30 years’ experience in capital markets globally, advising the boards of technology and healthcare-based organisations, and with a significant network of institutional and private wealth investors globally. He is an immediate past Executive Director of Canaccord Genuity and previously held executive senior corporate banking roles with Shaw and Partners and Lodge Partners.

Mr Sharp has Bachelors Economics and Law and is a CFA Charter Holder.

Mr Dignam leaves the Board having joined in February 2016 at the time of the Company’s Reverse Takeover transaction. He has been involved in the Company’s highly active M&A program that has included the acquisition of MKM Health, Patientrack, and ExtraMed and is Chair of the Audit and Risk Committee.

Commenting on the board renewal, Alcidion Chair Ms. Rebecca Wilson said: “Aligned with our growth strategy, is our forward-thinking position to evaluating the skills and experience of the board to support Alcidion’s next phase of growth. This board-led succession plan ensures a measured process of evolving the board to contribute fresh thinking, differentiated experiences, and relevance as we continue our growth path.”

“Victoria and Daniel bring significant, relevant experience to the Alcidion board, as we continue to expand our global presence as a digital health company at the frontier of unlocking and managing data to benefit clinicians and improve healthcare outcomes.”

“I’d like to thank Nick for his guidance and leadership since joining Alcidion in 2016 and his active involvement as the Chair of Audit and Risk, and member of the M&A sub-committee.”

Authorised for ASX release by the Board of Directors of Alcidion Group Limited.